Estrella Immunopharma, Inc.

NASDAQ: ESLA · Healthcare · Biotechnology

PublicHQ EmeryVille, CA · AlamedaCIK 0001844417Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 18DQ —GM —SS 27

v0.1 · 35/100 weight · pillars only

↑ market scale, filing timeliness · ↓ workforce scale, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$13.1M

Employees

as of 2026-08-20

Market cap

$31.4M

as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$13.1M-$13.1M2025

Operating income-$13.1M-$13.1M2025

Total assets$3.2M$3.2M2025

Liabilities$13.5M$13.5M2025

Equity-$10.4M-$10.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Estrella Immunopharma, Inc.’s financial profile?

Estrella Immunopharma, Inc. earned -$13.1M in FY2025 net income.

Peers · Healthcare

Obsidian Therapeutics Inc.——MIRA Pharmaceuticals, Inc.——Lantern Pharma Inc.——LeonaBio, Inc.——Sernova Corp.——Sangamo Therapeutics, Inc.——

Neighbors

Alameda →

Lam Research Corporation$18.4B85A Ross Stores, Inc.$22.8B79B+Block, Inc.$24.2B69B PG&E Corporation$24.9B70B Workday, Inc.$9.6B80B+Veeva Systems Inc.$3.2B81B+

Key facts

CEOCheng Liu

SectorHealthcare

IndustryBiotechnology

HeadquartersEmeryVille, CA

ExchangeNASDAQ: ESLA

Employees3

IPO date2021-09-14

Latest filings

8-K2026-08-21 10-Q2026-08-13 8-K2026-06-30 DEF 14A2026-05-27 10-Q2026-05-18 10-K2026-03-18 8-K2026-01-13 8-K2026-01-06

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.